The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2021 | Practical aspects of CAR T-cell therapy
Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, gives an overview of the topics discussed in the session he chaired on practical aspects of CAR T-cell therapy. CAR T-cell immunotherapy has radically altered the treatment of B-cell malignancies. Prof. Jäger outlines that in the setting of diffuse large B-cell lymphoma, the approved CAR-T products are being integrated into daily clinical practice. However, patient selection remains a challenge in the field. The new and exciting field of BCMA CAR T-cells in multiple myeloma was also addressed during the session. This interview took place during the 3rd European CAR T-cell Meeting.
Disclosures
Grant, personal fees, and nonfinancial support from Novartis, Bristol Myers Squibb/Celgene, Gilead, Janssen, Merck, and Roche
Grant and personal fees from Sanofi
Personal fees and nonfinancial support from AbbVie, Amgen, AOP Orphan, Miltenyi Biotec, Sandoz, and Takeda
